I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Value Digger holds MSc. in Electrical Engineering, speaks four languages (English, French, Greek, German) and has lived in the U.S. for many years. Also, he is a full-time investor and a freelance writer with one of the highest Followers per Article (F/A) rates in Seeking Alpha. His F/A rate in Seeking Alpha is above 30.
After creating "Nathan's Bulletin" (a subscription-based investment guide for investors who can't afford a financial advisor), Value Digger launched a subscription-based Premium Service in Seeking Alpha entitled "A Fundamental Investor's Stock Club" which includes an unparalleled, actively-managed and high-return Portfolio of unknown and/or underfollowed stocks. Regularly updated and detailed lists in his Premium Posts PROVE these high returns. For reference, when Value Digger was managing money in the early 2000s, his Portfolio's annual ROI consistently exceeded 50%. His Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends.
When it comes to his publicly-available picks and his free Seeking Alpha articles, Value Digger is ranked in the TOP-50 with a success rate of over 80%, an average return per recommendation of over 30% and a 5-star rating according to TipRanks.com, which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks 9,000 financial experts worldwide.
After almost 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), Value Digger has formulated a deep understanding of valuation analysis and his investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, he has created a unique proprietary database with thousands of publicly-traded companies per sector, which helps him spot the bargains and the bubbles before many investors find them.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
Mr. Hui has been involved in the equity markets since 1980, both on the buy side and the sell side. He is a CFA Charterholder, and has presented numerous papers to quantitative discussion groups (Sample topics include: How Global are Resource Sectors).
JDT investments is an investment group composed of three brothers named John, Joel, and Jacob Damerow. We look for new information, ask questions, and make informed trades based on our research. We deal primarily with small-cap stocks, and are fascinated with the biotech sector as a whole. We wish to present facts to others, and to inform individuals about new changes in the sector. We believe this area offers the greatest potential, if invested in wisely of course, and we strive to distribute that potential to our family, friends, and all of those who are eager to hear our opinions.Long Athersys.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution.
My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
Old school investment analysis by 30 year stock market veteran Stan Barton.
The past editor of STOCK ACTION advisory letter and past coordinator of the MENSA investment group is now helping successful people develop and preserve their legacy at Barton Legacy Advisor, LLC.
For a free consultation contact him at www.bartonla.com
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Tickerscores provides investors access to independent investment research on over 450 precious metals stocks. Using a universal scoring algorithm composed of 20+ variables,Tickerscores, allows investors to compare these stocks head-to-head in a unique visual format.
I have been trading part time for the past 10 years, focusing on swing trades and identifying how different stocks will "inhale and exhale" through the market. My primary targets are in the $2-$10 range, averaging over 2 million shares traded daily, and looking for an upswing. My goal is to average 10% per month, but will hold on for the long run with stocks that I believe in.
Stephan Bogner is mining analyst at Rockstone Research, he has independently analyzed capital markets and resource stocks for more than 11 years. He is also CEO at Elementum International AG of Switzerland trading precious metals and storing them in a high-security vaulting facility within the St. Gotthard Mountain Massif in Central Switzerland which is a duty-free zone. Bogner earned his degree in economics in 2004 at the International School of Management in Dortmund, Germany. He spent five years in Dubai brokering and reselling physical commodities and now resides in Zurich, Switzerland.
Diplom-Kaufmann Stephan Bogner began his academic studies in economics at the International School of Management in Dortmund (Germany) and was one of many who was hooked by the thrilling lectures of Professor Bocker on economic and monetary systems. Yet he was (and still is) the only student of the university that wrote a diploma thesis on precious metals as a protection against inflation (“Gold in a macroeconomic context with special consideration of the price formation process”) that was completed in 2002 under the supervision of Professor Bocker. Mr Bogner specialised in Finance & Asset Management, Production & Logistics and International Law & Entrepreneurship. He also studied at the European Business School in London (UK) and the University of Queensland in Brisbane (Australia).
In 2003, he started working closely with Ferdinand Lips, among others to publish and market his latest bestseller (“Gold Wars – The Battle Against Sound Money As Seen From A Swiss Perspective“) in the German-speaking countries. He revised and translated the English version into German (“Die Gold Verschwörung”). In 2004, he went to work at the biggest gold market in the world (Dubai), where he started up two companies that were specialised in re-selling and brokering physical commodities and consulting with publicly-listed mining companies. Moreover, he was co-founder and, until late 2006, partner of the first German silver stockletter and online information platform (Silberinfo.com) besides dealing with coins and bars.
Mr Bogner is an active analyst for several research firms, institutional and private investors and family offices, mainly for the analysis and valuation of capital markets and publicly-listed companies with a focus on geology, exploration, development and production of resource deposits. Since years, he lives in Zurich (Switzerland) and regularly publishes articles in German and English about economic contexts, currencies, commodities and companies active in exploration and mining of natural resources worldwide.
My name is Manny Backus.
Before you read any further, I want you to know a few things about me...
"Hey Manny... I just wanted to say thanks. I've been with you for about five months and I've been averaging about $5,923 a month, which is like $29,600..."
-- Bill Chandler, Glendale, Arizona
I am not your average professional stock trader. I'm not a stockbroker or individual investment advisor of any type. I've never worked at a big brokerage or had any kind of securities license at all. Nor do I have the Ivy League MBA that most financial "experts" consider a requirement.
The bottom line is all of these things are great achievements and look good hanging up on your wall, but they don't automatically make you a proficient trader.
What I do have is a tested intelligence quotient of 157. According to "IQ and the Wealth of Nations" by Richard Lynn, the average IQ of all United States residents is 98.
I also posses a killer instinct and a strategic mindset due to my early childhood training in the arena of international chess. But during my teenage years, my passion for the game of chess took a back seat to my obsession with online trading. After participating in several stock-picking competitions, I noticed certain people continued beating the market consistently.
There were only a handful of these super traders, but that reaffirmed my belief there must exist some sort of secret technique to earn money consistently in the stock market.
That's when I decided to parlay the tactical ability, the power to focus, and the schematic thinking that I learned from playing chess into the skill of picking winning stocks.
You see, chess is part tactics, and part ability to focus and remain unemotional. In chess, the player is always trying to challenge himself to try to guess the next move on the board. In stock trading, the trader is always trying to challenge himself to try to predict the next move of a stock. They're very similar disciplines.
Chess-playing is also based on war. You have to kill or be killed. A "killer move" is one wherein you have to kill on the first move. I used this "killer move" technique to devise the quickest way to make a killing with stocks that are getting ready to skyrocket or plummet.
Believe it or not, skilled chess players are often the best problem-solvers in any given situation. They are also known for their keen ability to grasp the inner workings of any system or apparatus -- tangible or intangible -- faster than average individuals? For instance, a study undertaken by Bankers Trust in New York found that chess players learned the tricks of the banker's trade at a more rapid rate than non-chess players -- even if the latter held MBAs."
By taking the principles I learned from the complex game of chess, I decided to give the stock market a try. I found that the systematic, detached and highly analytical approach it took to become a champion chess player was ideally suited to active trading.
Not the sleepy, Blue-Chip-life-sentence kind of investing most American money-managers practice (the “poor returns” kind)...
But aggressive, winner-take-all trading with but one objective: A fast, lucrative “checkmate” over the fickle moves of the markets.
"I've profited $4,000 after trading commissions... Manny has made not only myself, but many others, lots of money over the past few months since I started, and I have no doubt it will continue from here on in. Thank you, Manny."
-- Angel Lennox, Toronto, Canada
In 2002, I founded Wealthpire, Inc. and have successfully ran several trading research services. I have literally hundreds of letters from grateful readers expressing their wonderful success stories with my services. Read what some of my satisfied customers have to say here:
Unlike the folks who run a lot of other advisories out there, I have strict scruples about never artificially manipulating the market with the services I publish. That’s why you don’t see my name on any micro-cap tech-stock. Recommending positions in these tiny firms to more than a handful of people at a time can cause them to spike up in price on even a small uptick in volume.
I'm an ethical trader. That's why all of my services have a limit to the number of subscribers that are allowed to join.
My main goal is to use my knowledge, expertise and experience to help the average street-level investor to have a fun and profitable experience in the market. You can learn more about my services here:
I am a real estate developer and worked on dozens of projects over the last 20 years. I am also a market enthusiast enjoy trading companies in sevice sector, media and medical sectors.
I graduated Baruch College with a BBA in 1976.
Dustin Moore is a researcher and analyst focusing on overlooked and undervalued investments. He enjoys analyzing under-the-radar companies with massive upside potential and those with favorable risk/reward ratios.
On Twitter! @dustinrmoore https://twitter.com/dustinrmoore
Engineer by trade and passion. Have worked internationally for over three decades, running my own business. I hold a PhD in engineering, but honestly believe that the school of hard knocks has taught me lessons that are more applicable to my writing here on Seeking Alpha.
My investing interests mostly concern the resource sector, with a focus on precious metals, base metals and energy stocks of all sizes. My research explicitly includes small- and micro-cap juniors, and I try to manage the associated risks in a methodical manner.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments.
My level of trading escalated after graduating from college, primarily as a result of my relationship with the founder of the Silicon Valley venture capital firm, Institutional Venture Partners, (Netflix, Twitter, Oracle). By focusing on VC backed companies, I soon learned the advantage of investing in promising companies before they became household names. My interest in startups has never waned, and has become my primary focus today.
Eugene Eliot Narrett was born on December 27, 1948. He died on the night of December 6, 2013. Having just left an art gallery in Brattleboro, Vermont, where his paintings were on display, he crossed Union Street and was struck by a hit and run driver.
Professor Narrett was the first of five sons born to Dr. Sidney S. Narrett and Mrs. Beatrice Narrett.
Professor Narrett grew up in Passaic and Clifton, New Jersey. In 1963, at the age of fifteen, he won the Quality of Latin Certificate of Merit from the Philadelphia Classical Society. He attended Upper Montclair College High School and matriculated at Columbia University.
Professor Narrett graduated from Columbia in 1970 with a BA in Art History. He received his Masters degree with Honors in English and Comparative Literature in 1975 and his Ph.D in 1978 in these same disciplines all from Columbia University.
Professor Narrett’s dissertation on the Romantic poet, Percy Bysshe Shelley, The Comedic Vision of Shelley's Poetry, was written under the Columbia University scholar and professor, Karl Kroeber, who taught for nearly half a century in the English and comparative literature department. At the time his dissertation was completed, Professor Kroeber labelled Eugene Narrett as the greatest interpreter of Shelley extant.
Professor Narrett had a thirty plus year experience as a College teacher and was a published author in comparative literature, poetry, and art criticism. In 2010, Professor Narrett published in the English-American Association Journal, Identity, Theft, and Image Play in Coleridge. In 2010, Professor Narrett also authored a series of essays on Nietzsche and Schopenhauer and other western authors commenting on the nature of Western culture and how their views make use of or reflect on the relation of Judaism to the West.
In addition, Professor Narrett was an exhibiting artist (1977-92) and had gallery shows in New York City, Boston, Cambridge and Maynard Massachusetts and most recently and fatefully in Brattleboro, Vermont. He was also an accomplished self-taught flute player who once entertained strollers in the parks of Salzburg, Austria.
Professor Narrett taught, designed, created and directed many Liberal Arts courses and programs in fields including Art, Art History, History, Literature and Philosophy. His wide-ranging knowledge of history and his ability to integrate disciplines provided a comprehensive overview and rare insight into the most challenging conflicts and currents of our times. He published extensively on American politics and culture and on geopolitics and the Middle East. He is the author of three books: Gathered against Jerusalem: Essays on a False Peace; Israel Awakened: a Chronicle of the Oslo War; and Israel and the Endtimes: writings on the logic and surface turbulence of History (2006).
For much of his published work and radio guest appearances please see Israelendtimes.com as well as Amazon.com.
On language please see: http://www.webcommentary.com/php/ShowArticle.php?id=narrette&date=060924
As interpreter of Shakespeare please see: http://israelendtimes.com/blog/2010/08/28/thoughts-from-shakespeare.htm
Professor Narrett’s lifetime of scholarship and effort to find the essence in human behavior, as manifested in literature, art, and geo-politics came to a corporeal conclusion on a dark night in December but he always carried and forever will his soul carry the banner of learning and knowledge.
Professor Narrett was survived by his son, Gabriel Narrett and four younger brothers, David, Zachary, Seth and Matthew.
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
Investor with more than 5 years experience trading commodities, gold and silver miners, exploration companies, oil and gas, platinum and other hard assets.
The investment style is part contrarian/value and I actively seek investments in distressed sectors.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
I have been a professional writer for over 20 years. I also have enjoyed searching micro and nano cap companies looking for hidden gems. Having grown up around stock brokers and commodities traders I have seen the business from both sides. I have been an investor in the market for most of my life.
Invest. Manage risk. Communicate. Educate yourself. Make profits. .
My name is Todd Johnson. I’m a family man, sports fiend, health nut, technology buff, long-time stock investor, and a very lucky mountain climber, all of which has shaped my philosophy as a professional investor for the last 30 years. As my interests might suggest, I am always looking for the upside while striving to minimize risks.
My new passion, which I have realized through DividendLab.com project, is helping other investors learn more about investing; investing in stocks and other assets that are subject to wide price swings can actually enhance their returns when the right investment strategy is applied. To that end, I read company 10k and 10q statements so they can skip them. I compile and analyze the market research that isn’t always at their fingertips. And I don’t make any investment recommendation without committing my own funds first, which is the purest form of accountability.
I have a MBA in Healthcare Administration and Finance, a BS in Pharmacy, and a Doctorate degree in Pharmacy/Medicine. Investing in Biotechnology companies is my passion and I am also currently actively working in a teaching hospital. Also previously worked in the Pharmaceutical industry in regulatory affairs. My investment philosophy is investing in companies that you are familiar with and like to use their products and services. Because if you like it so will everyone else. Over 20 years of investment experience mostly in the healthcare.